Pharmacotherapy for the Different Phenotypes of Airways Disease
In a random community sample of people 18-75 years with wheeze and dyspnea, does the response to salbutamol 400 mcg once, iprotropium 80 mcg once or budesonide 800 mcg daily for 12 weeks differ between airways disease phenotypes in lung function, disease control and quality of life?
Medical Reseach Institute of New Zealand
16,500 participants
Nov 15, 2010
Interventional
Conditions
Summary
Chronic obstructive pulmonary disease (COPD) and asthma are the most common respiratory diseases in the community. People with these diseases differ in the way the disease manifests itself and some people have features of both diseases. We know that the best medications for asthma and COPD are different but we do not know if best treatment differs between the different types of asthma, COPD and the overlap of the two conditions. This study will answer this question by identifying people in the community with respiratory disease, assessing how the disease manifests in individuals and the effectiveness of three different standard inhaled medications. We will then group individuals into different clusters (types or patterns of disease manifestation) and determine which clusters respond to which different medication. This information will guide doctors who are treating these diseases.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1. Ipratropium 80 mcg inhaled single dose 2.Salbutamol 400 mcg inhaled single dose 3. Budesonide 400 mcg inhaled twice daily for 12 weeks All participants will receive all interventions in the sequence 1, 2, 3. Interventions 1 and 2 to be administered 1-4 weeks apart. Intervention 3 to be administered over the 12 weeks immediately following intervention 2.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000666022